HFA Premium Access

Heart failure with preserved, mid-range and reduced ejection fraction in non-Western countries

Presentation

About the speaker

Doctor Hisham Dokainish

McMaster University, Hamilton (Canada)
7 presentations
1 follower

11 more presentations in this session

Association between sacubitril/valsartan initiation and health status outcomes in heart failure with reduced ejection fraction: findings from the CHAMP-HF registry

Speaker: Doctor Y. Khariton (Kansas City, US)

Thumbnail

Discussion - Sacubitril/Valsartan initiation and health status outcomes in HFrEF

Thumbnail

Subtle ventricular dysfunction outperforms other risk markers in patients with coronary artery disease

Speaker: Professor D. Kotecha (Birmingham, GB)

Thumbnail

Discussion - ARM-CAD

Thumbnail

Rivaroxaban plus aspirin in patients with and without heart failure and chronic coronary or peripheral artery disease: the COMPASS trial

Speaker: Professor K. Branch (Seattle, US)

Thumbnail

Access the full session

Late breaking trial IV - Registries

Speakers: Doctor H. Dokainish, Doctor Y. Khariton, Professor D. Kotecha, Professor K. Branch
Thumbnail

About the event

Image

Heart Failure 2018 & World Congress on Acute Heart Failure

26 May - 29 May 2018

Sessions Presentations

Related content

Open Access

Definition and pathophysiological mechanisms of HFpEF.

29 August 2021

ESC Premium Access

Applying the ESC 2016, the H2FPEF, and the HFA-PEFF diagnostic algorithms for heart failure with preserved ejection fraction to the general population - a comparative approach

28 August 2021

Open Access

Classification of HF and diagnosis and treatment of HFmrEF and HFpEF.

27 August 2021

This platform is supported by

logo Novo Nordisk